110 related articles for article (PubMed ID: 29330751)
1. Prospective trial evaluating the sensitivity and specificity of 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine (18F-DOPA) PET and MRI in patients with recurrent gliomas.
Youland RS; Pafundi DH; Brinkmann DH; Lowe VJ; Morris JM; Kemp BJ; Hunt CH; Giannini C; Parney IF; Laack NN
J Neurooncol; 2018 May; 137(3):583-591. PubMed ID: 29330751
[TBL] [Abstract][Full Text] [Related]
2.
Patel CB; Fazzari E; Chakhoyan A; Yao J; Raymond C; Nguyen H; Manoukian J; Nguyen N; Pope W; Cloughesy TF; Nghiemphu PL; Czernin J; Lai A; Ellingson BM
J Neurooncol; 2018 Sep; 139(2):399-409. PubMed ID: 29679199
[TBL] [Abstract][Full Text] [Related]
3. The diagnostic accuracy of detecting malignant transformation of low-grade glioma using O-(2-[18F]fluoroethyl)-l-tyrosine positron emission tomography: a retrospective study.
Bashir A; Brennum J; Broholm H; Law I
J Neurosurg; 2018 Apr; 130(2):451-464. PubMed ID: 29624154
[TBL] [Abstract][Full Text] [Related]
4. The role of LAT1 in (18)F-DOPA uptake in malignant gliomas.
Youland RS; Kitange GJ; Peterson TE; Pafundi DH; Ramiscal JA; Pokorny JL; Giannini C; Laack NN; Parney IF; Lowe VJ; Brinkmann DH; Sarkaria JN
J Neurooncol; 2013 Jan; 111(1):11-8. PubMed ID: 23086431
[TBL] [Abstract][Full Text] [Related]
5. Amino acid PET vs. RANO MRI for prediction of overall survival in patients with recurrent high grade glioma under bevacizumab therapy.
Chaban A; Waschulzik B; Bernhardt D; Delbridge C; Schmidt-Graf F; Wagner A; Wiestler B; Weber W; Yakushev I
Eur J Nucl Med Mol Imaging; 2024 May; 51(6):1698-1702. PubMed ID: 38228970
[TBL] [Abstract][Full Text] [Related]
6. Tumour growth rate predicts overall survival in patients with recurrent WHO grade 4 glioma.
Pang JHW; Saffari SE; Lee GR; Yu WY; Lim CCT; Lim KC; Lee CC; Koh WY; Chia WTD; Chua KLM; Tham CK; Low YYS; Ng WH; Low CYD; Lin X
BMC Med Imaging; 2024 May; 24(1):125. PubMed ID: 38802734
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic validity and reliability of BT-RADS in the management of recurrent high-grade glioma.
Ebaid NY; Ahmed RN; Assy MM; Amin MI; Alaa Eldin AM; Alsowey AM; Abdelhay RM
J Neuroradiol; 2024 Jun; 51(4):101190. PubMed ID: 38492800
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of
Somme F; Bender L; Namer IJ; Noël G; Bund C
Cancer Imaging; 2020 Oct; 20(1):70. PubMed ID: 33023662
[TBL] [Abstract][Full Text] [Related]
9. Optical biopsy identification and grading of gliomas using label-free visible resonance Raman spectroscopy.
Zhou Y; Liu CH; Wu B; Yu X; Cheng G; Zhu K; Wang K; Zhang C; Zhao M; Zong R; Zhang L; Shi L; Alfano RR
J Biomed Opt; 2019 Sep; 24(9):1-12. PubMed ID: 31512439
[TBL] [Abstract][Full Text] [Related]
10. Post-ictal changes presenting as late pseudoprogression on MRI and PET in a patient with diffuse glioma: Case report and brief literature review.
Nair SM; Sahu A; Dasgupta A; Puranik A; Gupta T
Neuroradiol J; 2024 Apr; 37(2):229-233. PubMed ID: 37002537
[TBL] [Abstract][Full Text] [Related]
11. Added value of dynamic contrast-enhanced MR imaging in deep learning-based prediction of local recurrence in grade 4 adult-type diffuse gliomas patients.
Yoon J; Baek N; Yoo RE; Choi SH; Kim TM; Park CK; Park SH; Won JK; Lee JH; Lee ST; Choi KS; Lee JY; Hwang I; Kang KM; Yun TJ
Sci Rep; 2024 Jan; 14(1):2171. PubMed ID: 38273075
[TBL] [Abstract][Full Text] [Related]
12. Measure what is measurable: PET RANO 1.0 criteria for interpretation of amino acid PET of diffuse gliomas.
Albert NL; Preusser M
Neuro Oncol; 2024 Mar; 26(3):401-402. PubMed ID: 38165287
[No Abstract] [Full Text] [Related]
13. 6-[18F]fluoro-L-DOPA: a well-established neurotracer with expanding application spectrum and strongly improved radiosyntheses.
Pretze M; Wängler C; Wängler B
Biomed Res Int; 2014; 2014():674063. PubMed ID: 24987698
[TBL] [Abstract][Full Text] [Related]
14. Single-nucleus expression characterization of non-enhancing region of recurrent high-grade glioma.
Patel KS; Tessema KK; Kawaguchi R; Dudley L; Alvarado AG; Muthukrishnan SD; Perryman T; Hagiwara A; Swarup V; Liau LM; Wang AC; Yong W; Geschwind DH; Nakano I; Goldman SA; Everson RG; Ellingson BM; Kornblum HI
Neurooncol Adv; 2024; 6(1):vdae005. PubMed ID: 38616896
[TBL] [Abstract][Full Text] [Related]
15.
Humbert O; Bourg V; Mondot L; Gal J; Bondiau PY; Fontaine D; Saada-Bouzid E; Paquet M; Chardin D; Almairac F; Vandenbos F; Darcourt J
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):558-568. PubMed ID: 30612162
[TBL] [Abstract][Full Text] [Related]
16. Comparison Between 18F-Dopa and 18F-Fet PET/CT in Patients with Suspicious Recurrent High Grade Glioma: A Literature Review and Our Experience.
Evangelista L; Cuppari L; Bellu L; Bertin D; Caccese M; Reccia P; Zagonel V; Lombardi G
Curr Radiopharm; 2019; 12(3):220-228. PubMed ID: 30644351
[TBL] [Abstract][Full Text] [Related]
17. Accuracy of
Yu J; Zheng J; Xu W; Weng J; Gao L; Tao L; Liang F; Zhang J
World Neurosurg; 2018 Jun; 114():e1211-e1224. PubMed ID: 29625311
[TBL] [Abstract][Full Text] [Related]
18. Conventional and Advanced Imaging Techniques in Post-treatment Glioma Imaging.
Li AY; Iv M
Front Radiol; 2022; 2():883293. PubMed ID: 37492665
[TBL] [Abstract][Full Text] [Related]
19. Disease Assessments in Patients with Glioblastoma.
Phillips KA; Kamson DO; Schiff D
Curr Oncol Rep; 2023 Sep; 25(9):1057-1069. PubMed ID: 37470973
[TBL] [Abstract][Full Text] [Related]
20. Added value of [
Darcourt J; Chardin D; Bourg V; Gal J; Schiappa R; Blonski M; Koulibaly PM; Almairac F; Mondot L; Le Jeune F; Collombier L; Kas A; Taillandier L; Verger A
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2727-2735. PubMed ID: 37086272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
